(19)
(11) EP 4 441 500 A1

(12)

(43) Date of publication:
09.10.2024 Bulletin 2024/41

(21) Application number: 22830715.3

(22) Date of filing: 05.12.2022
(51) International Patent Classification (IPC): 
G01N 33/50(2006.01)
G01N 33/566(2006.01)
A61K 39/00(2006.01)
(52) Cooperative Patent Classification (CPC):
G01N 33/5023; G01N 33/566
(86) International application number:
PCT/EP2022/084451
(87) International publication number:
WO 2023/099788 (08.06.2023 Gazette 2023/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 03.12.2021 EP 21212178

(71) Applicant: Neurimmune AG
8952 Schlieren (CH)

(72) Inventor:
  • MICHALON, Aubin
    5400 Baden (CH)

(74) Representative: Witthoff Jaekel Steinecke Patentanwälte PartG mbB 
Postfach 1140
52412 Jülich
52412 Jülich (DE)

   


(54) NOVEL POTENCY ASSAY FOR ANTIBODY-BASED DRUGS AND USEFUL MEANS THEREFOR